Innoviva (INVA) Tops Q3 EPS by 71c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. GOOGL
8. RTX
9. TSLA
10. CRWV

Go back to Innoviva (INVA) Tops Q3 EPS by 71c

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 1, 2023 4:15 PM EDT

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023

Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter

Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023

Repurchased $11.0 million of common stock

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified holding company with a portfolio of royalties and other healthcare assets,... More